Ninth & Tenth Cases of PML in Tysabri Patients Reported
On June 19, 2009, Biogen Idec Inc. said a ninth Tysabri patient developed a potentially deadly brain infection since the drug was reintroduced to the market in 2006. The drug, which treats multiple sclerosis, was pulled from the market in 2005 following occurrences of a rare, but deadly, brain infection ...